Seres Therapeutics
MCRB
131 hedge funds and large institutions have $535M invested in Seres Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 45 increasing their positions, 54 reducing their positions, and 23 closing their positions.
59% more call options, than puts
Call options by funds: $3.16M | Put options by funds: $1.99M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.1% less ownership
Funds ownership: 4.2% → 4.1% (-0.1%)
11% less funds holding
Funds holding: 148 → 131 (-17)
17% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 54
17% less capital invested
Capital invested by funds: $642M → $535M (-$108M)
70% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.43M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$5.78M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.19M |
| 2 |
Goldman Sachs
New York
|
-$4.69M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.39M |
| 4 |
HF
HRT Financial
New York
|
-$2.83M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.69M |
MCRB Hedge Fund Activity: Q1 2022 in Review
131 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2022, worth a combined $535M — down 17% from $642M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MCRB and 7 opened new positions — a net loss of 16 holders — while 54 trimmed existing stakes and 45 added.
The largest buyer was Federated Hermes, adding an estimated $8.43M. The largest seller was Millennium Management, cutting an estimated $5.19M.
- 131 institutional investors held Seres Therapeutics (MCRB) as of Q1 2022, down from 148 in Q4 2021.
- Funds reported $535M of Seres Therapeutics stock for Q1 2022, down 17% quarter-over-quarter.
- 7 funds opened new Seres Therapeutics positions in Q1 2022 and 23 closed out, a net change of -16 holders.
- The largest Seres Therapeutics buyer in Q1 2022 was Federated Hermes, an estimated $8.43M added.
- The largest Seres Therapeutics seller in Q1 2022 was Millennium Management, an estimated $5.19M sold.
Based on aggregated 13F filings for Q1 2022.